Related Experiment Video
Updated: Mar 25, 2026
02:47
Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
2.1K
Eclampsia in Finland; 2006 to 2010
1Department of Obstetrics and Gynecology, University of Turku, Turku, Finland.
Acta Obstetricia Et Gynecologica Scandinavica
|February 27, 2016
Summary
Eclampsia incidence in Finland remains low, likely due to increased magnesium sulfate use. Further use of magnesium sulfate for prevention may further reduce eclampsia rates and complications.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Neurology
Background:
- Eclampsia poses a significant risk to maternal and fetal health.
- Magnesium sulfate has been a key management strategy for eclampsia in Finland since the late 1990s.
Purpose of the Study:
- To evaluate the incidence of eclampsia in Finland following the expanded use of magnesium sulfate.
- To assess the impact of magnesium sulfate on eclampsia-related maternal and fetal outcomes.
Main Methods:
- Retrospective analysis of eclampsia diagnoses from national registers (2006-2010).
- Review of medical records for identified cases.
- Calculation of eclampsia incidence per 10,000 deliveries.
Main Results:
- Eclampsia incidence was 1.5 per 10,000 deliveries (46 cases out of 295,447).
- No maternal deaths occurred; however, 46% experienced severe complications.
- Magnesium sulfate was used in 87% for treatment and 7% for prevention, with 8% perinatal mortality.
Conclusions:
- The low incidence of eclampsia in Finland is likely influenced by increased magnesium sulfate utilization.
- Magnesium sulfate use correlates with fewer recurrent seizures and prolonged complications.
- Prophylactic magnesium sulfate may further decrease eclampsia incidence, though some at-risk cases remain undetected.
